NFL Biosciences has enrolled the first participant in the Phase 2 TONIC study evaluating NFL-102, an immunotherapeutic candidate designed to aid smoking and nicotine cessation, the company announced Thursday.
The enrollment took place at the Eurofins Optimed clinical center in Gières, Isère, France, marking the official start of the multicenter, randomized, double-blind, placebo-controlled trial, Marketscreener reported.
The study plans to enroll 310 smokers across France. Its primary endpoint is four weeks of continuous abstinence verified by urinary cotinine measurement. Results from the initial Part A are expected to be analyzed and published in April 2027.
Regulatory clearance secured in October
On October 22, NFL Biosciences received the necessary regulatory authorizations from the French National Agency for Medicines and Health Products Safety (ANSM) and the Committee for the Protection of Persons (CPP), allowing the trial to proceed.
Adaptive design to select optimal dose
The trial employs an adaptive design that allows for the phased selection of the most effective dose among three initially evaluated. Part A is currently underway and involves the enrollment of 40 participants at the Eurofins Optimed site in Gières.
Upon completion of Part A, an Independent Data Monitoring Committee (IDMC) and the company will review unblinded safety and efficacy data. That analysis will determine which of the three initial doses will be dropped.
Part B to expand to approximately ten sites
The study will then proceed to Part B, which aims to enroll an additional 270 participants across roughly ten clinical centers in France. A further dose selection will occur after the enrollment of the first 150 participants in Part B.
The final 120 participants will be assigned to the selected dose or placebo for the final evaluation.
Two-injection regimen targets neuroplasticity
NFL-102 represents a second immunotherapeutic approach from the company to reach Phase 2. The candidate is designed to enhance neuroplasticity, which plays a role in addiction. Both of the company’s treatments are designed to be administered via just two subcutaneous injections one week apart.
The French National Agency for Medicines and Health Products Safety (ANSM) succeeded the French Agency for the Safety of Health Products (AFSSAPS) on 1 May 2012. AFSSAPS had been created by law on 4 January 1993, notably following the contaminated blood affair, and became operational in April 1993 with about 1,000 employees and 2,000 associated experts.
ANSM is responsible for assessing the benefits and risks of drugs and medical products throughout their life-cycle, balancing patient safety with access to novel therapies.
Shares trade at €0.3375
As of 14:52 CET on November 19, 2026, NFL Biosciences shares traded at €0.3375 on Euronext Paris, down 2.17% on the day, 10.00% over five days, and 71.35% since the start of the year, according to Marketscreener.
Worth a look